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ORIGINAL RESEARCH ARTICLE
Complementary tools such as lung ultrasound (LUS) and car-
diac biomarkers might aid in the diagnostic approach. 
LUS is highly sensitive for pulmonary congestion asses-
sment in HF (1), since the number and distribution of B-lines 
denote the amount of extravascular fluid in the lung.
Current guidelines included natriuretic peptides to mini-
mize HF diagnosis complexity, especially in the nonacute 
setting when echocardiography is not immediately available. 
In recent years, several cardiac biomarkers have been descri-
bed, reflecting different active pathogenic pathways in HF (2). 
The association of B-lines and N-terminal pro-brain natri-
uretic peptide (NT-proBNP) has been characterized in decom-
pensated acute HF patients. Nevertheless, there are few data 
on outpatients, and no data with other cardiac biomarkers. 
Accordingly, we investigated the correlation between B-lines 
and different biomarkers in outpatients with suspicion of HF 
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ABSTRACT
Introduction: The association of pulmonary congestion assessed by lung ultrasound (LUS) and biomarkers—other 
than N-terminal pro-brain natriuretic peptide (NT-proBNP)—is uncertain. 
Methods: We investigated the relationship between total B-line count by LUS and several biomarkers in outpa-
tients with suspicion of heart failure (HF). Primary care patients with suspected new-onset nonacute HF were 
evaluated both with a 12-scan LUS protocol (8 anterolateral areas plus 4 lower posterior thoracic areas) and 11 
inflammatory and cardiovascular biomarkers. A cardiologist blinded to LUS and biomarkers except NT-proBNP 
confirmed HF diagnosis. After log-transformation of biomarkers’ concentrations, unadjusted and adjusted cor-
relations were performed. 
Results: A total of 170 patients were included (age 76 ± 10 years, 67.6% women). HF diagnosis was confirmed 
in 38 (22.4%) patients. After adjustment by age, sex, body mass index, and renal function, total B-line sum sig-
nificantly correlated with NT-proBNP (R = 0.29, p < 0.001), growth/differentiation factor-15 (GDF-15; R = 0.23, 
p = 0.003), high-sensitive Troponin T (hsTnT; R = 0.36, p < 0.001), soluble interleukin-1 receptor-like 1 (sST2; 
R = 0.29, p < 0.001), cancer antigen 125 (CA-125; R = 0.17, p = 0.03), high-sensitivity C-reactive protein (hsCRP; 
R = 0.20, p = 0.009), and interleukin (IL)-6 (R = 0.23, p = 0.003). In contrast, IL-33 (R = −0.01, p = 0.93), IL-1β 
(R = −0.10, p = 0.20), soluble neprilysin (sNEP; R = 0.09, p = 0.24), tumor necrosis factor-alpha (TNF-α; R = 0.07, 
p = 0.39), and TNF-α receptor superfamily member 1A (TNFRSF1A; R = 0.14, p = 0.07) did not. 
Conclusions: Total B-line sum correlated significantly, although moderately, with congestion and several inflam-
mation biomarkers. Unexpectedly, the highest correlation found was with hsTnT.
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Introduction
Heart failure (HF) diagnosis is challenging in ambula-
tory patients, since signs and symptoms are mild and can 
be related with other diseases, and even to natural aging. 
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in the primary care setting. We hypothesized that biomarkers 
with multiple bio-profiling other than NT-proBNP might be 
associated with pulmonary congestion by LUS. 
Methods
Study design and patients
The present study is a biomarker subanalysis of a prospec-
tive cohort of ambulatory patients >50 years old, referred by 
their primary care physician to NT-proBNP test for suspected 
new-onset non-acute HF (July 2015 to January 2018) (3). We 
excluded patients with established HF diagnosis, pulmonary 
fibrosis, or radiological pachypleuritis. The study was perfor-
med in accordance with the Declaration of Helsinki; the local 
ethics committee approved the research protocol and infor-
med consent was obtained from all subjects.
Procedures
All inclusion visits were scheduled in a centralized setting, 
where the primary care physician investigator (LC, MD, AW) 
evaluated the patients, focusing on Framingham criteria, and 
performed LUS. Blood samples were collected for NT-proBNP 
measurement (XT), and serum aliquots were stored at −80°C 
prior to assay (ER-L). At a subsequent visit, a cardiologist 
investigator (GJ) assessed all participants and performed a 
transthoracic Doppler echocardiogram. This physician confir-
med HF diagnosis, following the European Society of Cardio-
logy guidelines. The cardiologist had access to the patients’ 
electronic records, including the primary care investigator 




NT-proBNP, high-sensitive Troponin T (hsTnT) and growth/
differentiation factor-15 (GDF-15) were measured by Cobas 
Elecsys® kits (Roche Diagnostics). Cancer antigen 125 (CA-
125) was tested by ARCHITECT CA 125 II assay (Abbott Dia-
gnostic). High-sensitivity C-reactive protein (hsCRP) was 
measured by hsCRP reagent (Beckman Coulter). Human solu-
ble neprilysin (NEP) and soluble interleukin-1 receptor-like 
1 (sST2) were measured by Human Soluble neprilysin/CD10 
ELISA kit (Aviscera Bioscience) and Presage® ST2 (Critical Dia-
gnostics) assays, respectively. Interleukin (IL)-1β, IL-33, IL-6, 
tumor necrosis factor-alpha (TNF-α), and TNF-α receptor 
superfamily member 1A (TNFRSF1A) were tested by Quanti-
kine® immunoassay kits (R&D Systems). 
NT-proBNP was analyzed after collection. The rest of the 
biomarkers were analyzed in the first or second freeze-thaw 
cycle.
Lung ultrasound
LUS was performed with a pocket device (V-scan simple 
model with a sectorial phased array transducer; General 
Electric®) and interpreted bench side. LUS was performed 
with patient in a seated position; 8 anterolateral thoracic 
areas plus 4 posterior lower areas were examined. Each of 
the 12 areas was classified according to the number of B-lines 
in the sagittal scan. A thoracic area was considered positive if 
≥3 B-lines were observed. Pleural effusion was considered as 
10 B-lines. LUS congestion was defined as 2 out of 6 positive 
scans in each hemithorax.
Transthoracic Doppler echocardiography
Echocardiographic study was performed using an iE33 
ultrasound system (Philips Medical Systems; Andover, Massa-
chusetts) with a S5-1 sector transducer (5.1 MHz bandwidth), 
and analyses were performed with an EchoPAC. 
Statistical analysis
Categorical values are described as absolute numbers 
(percentages) and continuous variables as means (standard 
deviations) or medians [interquartile ranges], depending on 
whether data distribution was normal as assessed by nor-
mal Q-Q plots. To assess the relationship of total B-line sum 
acquired by LUS with biomarkers’ concentrations, Pearson 
correlation was used after logarithmic transformation of 
biomarker levels; afterward, partial correlations adjusted by 
age and sex, and finally by age, sex, body mass index, and 
estimated glomerular filtration rate (eGFR) were performed. 
Analyses were performed using Statistical Package for the 
Social Sciences (SPSS) 24. A two-sided p < 0.05 was conside-
red significant.
Results
Table I shows baseline characteristic and biomarker 
values of the 170 patients included. They were elderly, pre-
dominantly women, obese or overweight, and mainly in New 
York Heart Association (NYHA) class II. HF diagnosis was con-
firmed in 38 (22.4%) patients, and only one had left ventricu-
lar ejection fraction (LVEF) < 40%. Patients with HF diagnosis 
had higher levels of all biomarkers except IL-33, IL-1β, and 
soluble neprilysin (sNEP). They also had a higher number of 
total B-line count (p < 0.001). Although 85% of patients had 
exertional dyspnea, only 17.1% had crackles, 9.4% orthop-
nea, and 3.5% paroxysmal nocturnal dyspnea.  
Correlations between total B-line sum and studied bio-
markers are shown in Table II. Unadjusted analyses sho-
wed that total B-line sum was significantly associated with 
NT-proBNP, GDF-15, hsTnT, sST2, CA-125, hsCRP, IL-6, and 
TNFRSF1A (R range 0.18-0.35), while IL-33, IL-1β, sNEP, and 
TNF-α levels were not associated with total B-line sum. After 
the adjustments for the four covariates, R values tended to 
slightly decrease except for hsTnT and TNFRSF1A that lost 
statistical significance. 
Discussion
Bedside LUS has appeared as a step forward for HF dia-
gnosis, and biomarkers other than NT-proBNP are currently 
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TABLE I - Demographic, clinical characteristics and biomarker levels of patients
Total 
n = 170 
HF diagnosis 
n = 38 
No HF diagnosis
n = 132 
p-value
Age, years 76 ± 10.4 81.2 ± 8.3 74.4 ± 10  <0.001
Female sex, n (%) 115 (67.6) 23 (60.5) 92 (69.7) 0.29
LVEF, % 63 ± 5.8 59.9 ± 7.2 63.8 ± 5  <0.001




 Valvular heart disease 
 Myocardial infarction 
 Atrial fibrillation 
 Obesity (BMI >30 kg/m2)















































Exertion dyspnea 145 (85.3) 36 (94.7) 109 (82.6) 0.06
Orthopnea 16 (9.4) 8 (21.1) 8 (6.1) 0.005
Paroxysmal nocturnal dyspnea 6 (3.5) 2 (5.3) 4 (3.0) 0.51
Lung crackles 29 (17.1) 11 (28.9) 18 (13.6) 0.03






























































Data are expressed as mean (standard deviation), median (percentiles 25th-75th), or absolute numbers (percentages).
BMI = body mass index; CA-125 = cancer antigen 125; COPD = chronic obstructive pulmonary disease; eGFR = estimated glomerular filtration rate;  
GDF-15 = growth differentiation factor 15; HF = heart failure; hsCRP = high-sensitivity C-reactive protein; hsTnT = high-sensitivity troponin T; IL = interleukin;  
LVEF = left ventricular ejection fraction; NT-proBNP = N-terminal pro-brain natriuretic peptide; NYHA = New York Heart Association; sNEP = soluble neprilysin; 
sST2 = soluble interleukin-1 receptor-like 1; TNF-α = tumor necrosis factor α; TNFRSF1A = TNF receptor superfamily member 1A.
under investigation. Although there is a growing interest on 
both, added value for better patient diagnosis and mana-
gement has scarcely been studied. In our study, we asses-
sed the correlation between B-lines and a biomarker panel 
in primary care outpatients with new-onset nonacute 
HF suspicion. Our results showed that (i) total B-line sum 
observed by LUS was significantly—although moderately—
associated with several biomarkers of active pathogenic 
pathways in HF, especially with those related to congestion 
and inflammation; and (ii) hsTnT, a biomarker related to 
Domingo et al  11
© 2020 The Authors. Published by AboutScience
myocardial injury, was mainly and unexpectedly associated 
with total B-line sum. 
HF diagnosis can be difficult at early stages, especially in 
women and old patients with comorbidities. Our patients 
were elderly, mainly women, and not very symptomatic. Less 
than 10% of patients had lung congestion symptoms and only 
17% crackles. In this context, HF was only confirmed in 22.4% 
of patients since Framingham criteria, despite being highly 
specific, have a poor sensitivity for HF diagnosis in ambula-
tory patients. 
Hand-held devices could be easily incorporated in pri-
mary care and have shown a good correlation with standard 
ultrasound equipment for B-line detection. In our study, we 
used the 8-zone technique adding 4 posterior zones since 
these areas are the first that show signs of congestion and 
could add accuracy in outpatients.
As expected and according to previous studies in acute 
HF, total B-line sum was significantly associated with NT-
proBNP levels. However, we projected a highest correlation, 
since increased intracardiac filling pressures often precede 
lung congestion. Nevertheless, in mildly symptomatic pri-
mary care patients, pulmonary congestion is not always 
present unlike hemodynamic dysfunction. sST2 levels also 
correlated with B-line count in a similar level that NT-proBNP. 
ST2 is a member of the IL-1 receptor family linked to myo-
cardial fibrosis and adverse remodeling, both related to 
diastolic dysfunction and increased end-diastolic pressures 
that can contribute to pulmonary congestion. sST2 has been 
described as a 3-in-1 biomarker and provides insight into the 
hemodynamic, inflammatory, and pro-fibrotic/remodeling 
burden of the myocardium (4). Total B-line sum also corre-
lated with GDF-15, a marker of cell injury inflammation, oxi-
dative stress, and hypoxia. These results are consistent with 
previous studies where GDF-15 may indicate a greater syste-
mic inflammatory response in old patients and those with HF 
and preserved EF (5), as was the population of our study. It is 
remarkable that these two biomarkers, being in part inflam-
matory biomarkers but also associated with other several 
pathogenic pathways in HF, correlated with total B-line sum 
in a greater degree than the more “pure” inflammatory ones 
(hsCRP, IL-1β, IL-33, IL-6, TNF-α, and TNFRSF1A).
Maybe the more remarkable finding was the high corre-
lation of total B-line sum with hsTnT, a biomarker of myocar-
dial injury frequently elevated in patients with HF without 
coronary ischemia. Unexpectedly, hsTnT correlation was 
even higher than that observed with NT-proBNP and sST2. 
Recently, Myhre et al (6) showed that high-sensitive car-
diac Troponin T (hs-cTnT) concentrations were associated 
with worse diastolic function, suggesting that high levels of 
hs-cTnT may serve as an early marker of subclinical altera-
tions in diastolic function that may lead to a predisposition 
to HF. 
Finally, although there was a statistically significantly cor-
relation between total B-line sum and CA-125, we anticipated 
a higher correlation, since both are surrogates of pulmonary 
and systemic congestion (7), respectively. Congestion plays a 
major role in acute HF syndromes; however, it is known that 
severity and organ distribution are largely heterogeneous. In 
fact, our primary care patients showed low percentages of 
congestion signs or symptoms. 
Limitations of our study include the limited sample size 
and the low incidence of HF since our target was primary care 
patients with mild symptoms and suspicion of HF. These facts 
might have an impact on the external validity of the study. 
Also HF diagnosis was performed by a single cardiologist. 
Although larger studies in diverse populations are needed, 
our data are hypotheses generating correlations between 
B-lines, a surrogate of pulmonary congestion, and of biomar-
kers in HF patients.
Conclusion
In primary care outpatients with new-onset nonacute 
HF suspicion, total B-line sum is significantly—although 
moderately—associated with several biomarkers of conge-
stion and inflammation, and remarkably with hsTnT. 
TABLE II - Correlations between total B-line sum and studied biomarkers
NT-proBNP GDF-15 hsTnT sST2 CA-125 hsCRP IL-6 IL-33 IL-1β sNEP TNF-α TNFRSF1A
Unadjusted
R 0.32 0.27 0.35 0.32 0.21 0.22 0.27 –0.02 –0.08 0.10 0.09 0.18
p-value <0.001 <0.001 <0.001 <0.001 0.007 0.004 <0.001 0.81 0.28 0.21 0.26 0.02
Adjusted by age and sex
R 0.29 0.23 0.34 0.30 0.19 0.21 0.24 –0.01 –0.11 0.09 0.08 0.15
p-value <0.001 0.003 <0.001 <0.001 0.02 0.007 0.002 0.93 0.18 0.24 0.32 0.06
Adjusted by age, sex, BMI, and eGFR*
R 0.29 0.23 0.36 0.29 0.17 0.20 0.23 –0.01 –0.10 0.09 0.07 0.14
p-value <0.001 0.003 <0.001 <0.001 0.03 0.009 0.003 0.93 0.20 0.24 0.39 0.07
*estimated by CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration).
BMI = body mass index; CA-125 = cancer antigen 125; eGFR = estimated glomerular filtration rate; GDF-15 = growth differentiation factor 15; hsCRP = high- 
sensitivity C-reactive protein; hsTnT = high-sensitivity troponin T; IL = interleukin; NT-proBNP = N-terminal pro-brain natriuretic peptide; sNEP = soluble neprilysin;  
sST2 = soluble interleukin-1 receptor-like 1; TNF-α = tumor necrosis factor α; TNFRSF1A = TNF receptor superfamily member 1A. 
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